The present invention provides vascular endothelial cell growth factor (hVEGF) antagonists, including monoclonal antibodies, hVEGF receptors, and hVEGF variants that inhibit the mitogenic, angiogenic, or other biological activity of hVEGF. The antagonists thus are useful for the treatment of diseases ...
The mechanism of resistance development to anti-VEGF therapy in ovarian cancer is unclear. We focused on the changes in tumour immunity post anti-VEGF therapy. The frequencies of immune cell populations and hypoxic conditions in the resistant murine tumo
First-line treatments of anti-EGFR and anti-EGFR targeted drugs combined with chemotherapy in metastaticcolorectal cancer:Meta-analysis and systematic revi... OBJECTIVE NCCN guidelines recommend that anti-VEGF or anti-EGFR as a standard regimen for first-line treatment of metastatic colorectal cancer(...
In theory, non-stop treatment with anti-VEGF drugs should be given to cancer patients as VEGF continues to be functional after discontinuation of treatment. However, during clinical practice, interrupted anti-VEGF regimens are used in cancer patients because of drug-related adverse effects, economic...
Plasma VEGF warrants further evaluation as a prognostic marker for treatment outcome in advanced breast cancer patients receiving anti-VEGF therapy. 展开 关键词: Humans Breast Neoplasms Vinblastine Vascular Endothelial Growth Factor A Antineoplastic Combined Chemotherapy Protocols Tumor Markers, Biological ...
Optimaltreatment duration of bevacizumab (BEV) combined with carboplatin andpaclitaxel in patients (pts) with primary epithelial ovarian (EOC), fallopiantube (FTC) or peritoneal cancer (PPC): A multicenter open-label randomized2-arm phase 3 ...
Anti-VEGF therapy has demonstrated clinical benefits in the first-line treatment of NSCLC. Central nervous system (CNS) metastases are a common occurrence among patients with lung cancer and confer significant morbidity and mortality. The risk of CNS hemorrhage in NSCLC patients receiving anti-VEGF ...
suppresses expression of ACE and the AT1R and inhibits cell growth and the production of vascular endothelial growth factor-alpha (VEGFa). Moreover, the results in vivo prove that the overexpression of ACE2 reduces the invasive capacity and the migration of non-small cell lung cancer11...
This is depicted by the scans of the patient shown in Figure 1 in the report by Gasperini et al.59 It is suggested that many such eyes may respond favourably to a change of in the anti-VEGF agent used.59 Others have referred to a lack of response to anti- VEGF drugs at the time ...
Our study suggests that the combination of a PD-1 antibody, an HDACi, and a VEGF antibody could be a promising treatment regimen for patients with MSS/pMMR advanced colorectal cancer. ClinicalTrials.gov registration: NCT04724239.This is a preview of subscription content, access via your ...